Xenon to Showcase New Long-Term Azetukalner Data at AES 2024
Xenon Pharmaceuticals (XENE) announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2024), scheduled for December 6-10, 2024 in Los Angeles. The company will present five posters featuring new long-term 36-month data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS). The presentations will also cover mental health and comorbidity burdens of FOS, along with new pre-clinical data from the company's early-stage Nav1.1 program. The company will host a Scientific Exhibit and maintain booths at the event to showcase their clinical and research programs.
Xenon Pharmaceuticals (XENE) ha annunciato numerose presentazioni al prossimo American Epilepsy Society Annual Meeting (AES 2024), che si terrà dal 6 al 10 dicembre 2024 a Los Angeles. L'azienda presenterà cinque poster contenenti nuovi dati a lungo termine di 36 mesi dallo studio in corso X-TOLE, un'estensione open-label, relativi all'azetukalner in pazienti con crisi a insorgenza focale (FOS). Le presentazioni tratteranno anche degli oneri relativi alla salute mentale e alla comorbilità delle FOS, insieme a nuovi dati pre-clinici del programma Nav1.1 dell'azienda. La compagnia ospiterà una mostra scientifica e avrà stand all'evento per presentare i propri programmi clinici e di ricerca.
Xenon Pharmaceuticals (XENE) anunció múltiples presentaciones en la próxima Reunión Anual de la Sociedad Americana de Epilepsia (AES 2024), programada del 6 al 10 de diciembre de 2024 en Los Ángeles. La empresa presentará cinco carteles con nuevos datos a largo plazo de 36 meses del estudio en curso X-TOLE, una extensión de etiqueta abierta, sobre azetukalner en pacientes con crisis de inicio focal (FOS). Las presentaciones también abordarán las cargas de salud mental y comorbilidad de las FOS, así como nuevos datos preclínicos del programa inicial Nav1.1 de la empresa. La compañía organizará una Exhibición Científica y mantendrá stands en el evento para mostrar sus programas clínicos y de investigación.
젠온 제약(XENE)는 2024년 12월 6일부터 10일까지 로스앤젤레스에서 열리는 미국 간질 학회 연례 회의(AES 2024)에서 여러 발표를 할 예정이라고 밝혔습니다. 이 회사는 초기 단계의 X-TOLE 개방형 연장 연구에서 아제투칼너를 사용한 초점 발작(FOS) 환자에 대한 새로운 장기 36개월 데이터를 담은 다섯 개의 포스터를 발표할 것입니다. 발표에서는 FOS의 정신 건강 및 동반 질병 부담과 함께, 회사의 초기 단계 Nav1.1 프로그램의 새로운 전임상 데이터도 다룰 것입니다. 회사는 과학 전시회를 주최하고 임상 및 연구 프로그램을 보여주기 위해 행사에 부스를 운영할 예정입니다.
Xenon Pharmaceuticals (XENE) a annoncé plusieurs présentations lors de la prochaine Réunion Annuelle de la Société Américaine d'Épilepsie (AES 2024), prévue du 6 au 10 décembre 2024 à Los Angeles. L'entreprise présentera cinq affiches contenant de nouvelles données à long terme de 36 mois de l'étude en cours X-TOLE, une extension en libre accès, concernant azetukalner chez les patients ayant des crises d'apparition focale (FOS). Les présentations aborderont également les charges de santé mentale et de comorbidité des FOS, ainsi que de nouvelles données précliniques du programme Nav1.1 de l'entreprise. L'entreprise organisera une exposition scientifique et maintiendra des stands lors de l'événement pour présenter ses programmes cliniques et de recherche.
Xenon Pharmaceuticals (XENE) kündigte zahlreiche Präsentationen auf dem bevorstehenden American Epilepsy Society Annual Meeting (AES 2024) an, das vom 6. bis 10. Dezember 2024 in Los Angeles stattfinden wird. Das Unternehmen wird fünf Poster mit neuen langfristigen 36-Monats-Daten aus der laufenden offenen X-TOLE-Erweiterungsstudie zu azetukalner bei Patienten mit fokalen Anfallsbeginn (FOS) präsentieren. Die Präsentationen werden auch die Belastungen der psychischen Gesundheit und Komorbidität von FOS sowie neue präklinische Daten aus dem frühen Nav1.1-Programm des Unternehmens behandeln. Das Unternehmen wird eine wissenschaftliche Ausstellung veranstalten und Stände auf der Veranstaltung betreiben, um seine klinischen und Forschungsprogramme vorzustellen.
- New long-term 36-month data from X-TOLE study to be presented
- Multiple presentations (5 posters) at major industry conference
- Advancing development of azetukalner, their most advanced clinical candidate
- None.
Insights
The upcoming presentation of 36-month long-term data from the X-TOLE open-label extension study for azetukalner is a routine conference update that doesn't reveal actual results or meaningful data. While the study's findings could be significant when presented, this announcement merely outlines planned poster presentations at AES 2024.
The five posters will cover:
- Long-term safety and efficacy data for azetukalner in focal epilepsy
- Mental health burden studies in focal onset seizures
- Comorbidity burden research
- Pre-clinical Nav1.1 program data in Dravet mouse models
Without actual data or results being disclosed, this news serves primarily as a schedule announcement for the upcoming scientific conference presentations.
- Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around mental health and comorbidity burdens of FOS
- New pre-clinical data from the Company’s Nav1.1 program
VANCOUVER, British Columbia and BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2024), taking place December 6-10, 2024 at the Los Angeles Convention Center in Los Angeles, CA. Five posters will be presented, featuring new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS), the mental health burden and comorbidity burdens of focal onset seizures, as well as new pre-clinical data from the Company’s early-stage Nav1.1 program.
- Poster Presentation #2.361: Long-term Safety and Efficacy of Azetukalner, a Novel, Potent Kv7 Potassium Channel Opener in Adults With Focal Epilepsy: Update From the Ongoing 7-year Open-Label Extension of X-TOLE
Jacqueline A. French, MD, New York University Grossman School of Medicine and NYU Langone Health
Author Session: Sunday, December 8 from 12 pm – 2 pm PT in South Hall H, Level 1
- Poster Presentation #2.347: Is the Mental Health Burden of Epilepsy Under-Recognized in Patients Reporting Focal Onset Seizures? A Patient-Reported Outcomes Study
Author Session: Sunday, December 8 from 12 pm – 2 pm PT in South Hall H, Level 1
- Poster Presentation #2.338: A Targeted Literature Review of Comorbidity Burden in Focal Onset Seizures
Author Session: Sunday, December 8 from 12 pm – 2 pm PT in South Hall H, Level 1
- Poster Presentation #3.389: Nav1.1 Potentiators Modulate Brain Rhythms Measured Through Quantitative Electrocorticography (qECoG) in a Dravet Mouse Model
Author Session: Monday, December 9 from 12 pm – 2 pm PT in South Hall K, Level 1
- Poster Presentation #3.395: Selective Potentiation of Nav1.1 Channels in Dravet Mice Restores Interneuron Function and Improves Motor Function
Author Session: Monday, December 9 from 12 pm – 2 pm PT in South Hall K, Level 1
Scientific Exhibit
Xenon is hosting a Scientific Exhibit to provide an overview of its clinical and research programs on Sunday, December 8, 2024 from 2 pm – 5 pm PT in Room 406A on level 2.
Exhibit Hall
Xenon is hosting booths #1721 and #1827 in the Exhibit Hall, which is scheduled to open at 12 pm PT on Saturday, December 7 and close on Monday, December 9, 2024 at 2 pm PT.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical trials; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs; and our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of market, industry, and regulatory conditions on clinical trial enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
What will Xenon Pharmaceuticals (XENE) present at AES 2024?
When and where is Xenon (XENE) presenting at AES 2024?
What is azetukalner and what is it being developed for by Xenon (XENE)?
